Department of Brain Health News
The department of brain health is dedicated to advancing research, education, and clinical care to benefit brain health and the care and treatment of people with brain disorders across the lifespan. The faculty specializes in several areas that range from basic to clinical research in neurodegenerative disease and stroke.
Current Brain Health News
A collection of top headlines featuring ÐÔÊӽ紫ý faculty and students.
Tenth annual report led by noted clinician-scientist Dr. Jeffrey Cummings tracks status, trends associated with 192 active clinical trials worldwide.
Some of the hottest headlines featuring ÐÔÊӽ紫ý faculty, staff, and students.
The top news stories starring university students and staff.
Data provided by ÐÔÊӽ紫ý researchers helped secure FDA approval for a new blood test to detect Alzheimer’s disease.
The top headlines featuring ÐÔÊӽ紫ý’s staff and students.
Brain Health In The News
Out now is the 10th annual Alzheimer's Drug Development Pipeline Report.
Several local and regional startups were showcased recently at ÐÔÊӽ紫ý Innovation Day, where Dr. Jeffrey Cummings, director of the Chambers-Grundy Center for Transformative Neuroscience in the Department of Brain Health at the Kirk Kerkorian School of Medicine at ÐÔÊӽ紫ý, was excited about the growth of the life sciences ecosystem.
While Alzheimer’s remains a complex disease, recent clinical trials and research efforts have expanded, emphasizing biomarkers and better patient targeting to improve drug development success rates.
Delayed and imprecise Alzheimer’s diagnoses in the UK are limiting patient access to clinical trials despite rapid growth in experimental treatments.
The number of national clinical trials for Alzheimer’s therapies has increased by 40 percent in the last decade. That’s according to ÐÔÊӽ紫ý brain health researcher Jeffrey Cummings’ 10th annual report, published Tuesday in the Alzheimer’s Association’s research journal.
Dr Jeffrey Cummings, of the ÐÔÊӽ紫ý, has published an annual review of clinical trials for Alzheimer’s drugs for the past decade. The latest review, published in Alzheimer’s & Dementia: Translational Research & Clinical Interventions, reveals a shifting approach to the disease, with fewer drugs designed to remove amyloid and more targeting tau, inflammation and other immune system pathways.
